Man Group’s Foghorn Therapeutics FHTX Stock Holding History

Man Group’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,855	Closed	-$104K	–	1789
2022 Q4	$101K	Buy	+15,855	New	+$120K	﹤0.01%	1906

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's FHTX Position: Q1 2023 in Review

Man Group sold out of Foghorn Therapeutics (FHTX) in Q1 2023, closing a stake of 15,855 shares — an estimated $104K sold.

Man Group first reported a position in FHTX in Q4 2022 and held it in 1 quarter. The position peaked at $101K in Q4 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q1 2023.

Man Group reported no remaining Foghorn Therapeutics position as of Q1 2023 after selling out during the quarter.
Man Group sold 15,855 Foghorn Therapeutics shares in Q1 2023, an estimated $104K.
Man Group first reported a position in Foghorn Therapeutics in Q4 2022 and held it in 1 quarter.
Man Group's Foghorn Therapeutics position peaked at $101K in Q4 2022.
60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.